Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: Patients were randomly assigned to D 3...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Petrioli, R, Pascucci, A, Conca, R, Chiriacò, G, Francini, E, Bargagli, G, Fiaschi, A I, Manganelli, A, De Rubertis, G, Barbanti, G, Ponchietti, R, Francini, G
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2011
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049601/
https://ncbi.nlm.nih.gov/pubmed/21285986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items